Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 179

1.

Enhancing viral vaccine production using engineered knockout vero cell lines - A second look.

Hoeksema F, Karpilow J, Luitjens A, Lagerwerf F, Havenga M, Groothuizen M, Gillissen G, Lemckert AAC, Jiang B, Tripp RA, Yallop C.

Vaccine. 2018 Apr 12;36(16):2093-2103. doi: 10.1016/j.vaccine.2018.03.010. Epub 2018 Mar 16.

2.

The Th1 immune response to Plasmodium falciparum circumsporozoite protein is boosted by adenovirus vectors 35 and 26 with a homologous insert.

Radosevic K, Rodriguez A, Lemckert AA, van der Meer M, Gillissen G, Warnar C, von Eyben R, Pau MG, Goudsmit J.

Clin Vaccine Immunol. 2010 Nov;17(11):1687-94. doi: 10.1128/CVI.00311-10. Epub 2010 Sep 8. Erratum in: Clin Vaccine Immunol. 2011 Feb;18(2):353.

3.

Evaluation of a prime-boost vaccine schedule with distinct adenovirus vectors against malaria in rhesus monkeys.

Rodríguez A, Mintardjo R, Tax D, Gillissen G, Custers J, Pau MG, Klap J, Santra S, Balachandran H, Letvin NL, Goudsmit J, Radosević K.

Vaccine. 2009 Oct 19;27(44):6226-33. doi: 10.1016/j.vaccine.2009.07.106. Epub 2009 Aug 15.

PMID:
19686691
4.

Impact of recombinant adenovirus serotype 35 priming versus boosting of a Plasmodium falciparum protein: characterization of T- and B-cell responses to liver-stage antigen 1.

Rodríguez A, Goudsmit J, Companjen A, Mintardjo R, Gillissen G, Tax D, Sijtsma J, Weverling GJ, Holterman L, Lanar DE, Havenga MJ, Radosevic K.

Infect Immun. 2008 Apr;76(4):1709-18. doi: 10.1128/IAI.01614-07. Epub 2008 Jan 22.

5.

High-level expression from two independent expression cassettes in replication-incompetent adenovirus type 35 vector.

Vogels R, Zuijdgeest D, van Meerendonk M, Companjen A, Gillissen G, Sijtsma J, Melis I, Holterman L, Radosevic K, Goudsmit J, Havenga MJ.

J Gen Virol. 2007 Nov;88(Pt 11):2915-24.

PMID:
17947512
6.

Increased immunogenicity of recombinant Ad35-based malaria vaccine through formulation with aluminium phosphate adjuvant.

Ophorst OJ, Radosević K, Klap JM, Sijtsma J, Gillissen G, Mintardjo R, van Ooij MJ, Holterman L, Companjen A, Goudsmit J, Havenga MJ.

Vaccine. 2007 Aug 29;25(35):6501-10. Epub 2007 Jun 29.

PMID:
17646036
7.

Protective immune responses to a recombinant adenovirus type 35 tuberculosis vaccine in two mouse strains: CD4 and CD8 T-cell epitope mapping and role of gamma interferon.

Radosevic K, Wieland CW, Rodriguez A, Weverling GJ, Mintardjo R, Gillissen G, Vogels R, Skeiky YA, Hone DM, Sadoff JC, van der Poll T, Havenga M, Goudsmit J.

Infect Immun. 2007 Aug;75(8):4105-15. Epub 2007 May 25.

8.

Human adenovirus type 35 vector for gene therapy of brain cancer: improved transduction and bypass of pre-existing anti-vector immunity in cancer patients.

Brouwer E, Havenga MJ, Ophorst O, de Leeuw B, Gijsbers L, Gillissen G, Hoeben RC, ter Horst M, Nanda D, Dirven C, Avezaat CJ, Goudsmit J, Sillevis Smitt P.

Cancer Gene Ther. 2007 Feb;14(2):211-9. Epub 2006 Nov 3.

PMID:
17082793
9.

Novel replication-incompetent adenoviral B-group vectors: high vector stability and yield in PER.C6 cells.

Havenga M, Vogels R, Zuijdgeest D, Radosevic K, Mueller S, Sieuwerts M, Weichold F, Damen I, Kaspers J, Lemckert A, van Meerendonk M, van der Vlugt R, Holterman L, Hone D, Skeiky Y, Mintardjo R, Gillissen G, Barouch D, Sadoff J, Goudsmit J.

J Gen Virol. 2006 Aug;87(Pt 8):2135-43.

PMID:
16847108
10.

Human CD46-transgenic mice in studies involving replication-incompetent adenoviral type 35 vectors.

Verhaagh S, de Jong E, Goudsmit J, Lecollinet S, Gillissen G, de Vries M, van Leuven K, Que I, Ouwehand K, Mintardjo R, Weverling GJ, Radosevic K, Richardson J, Eloit M, Lowik C, Quax P, Havenga M.

J Gen Virol. 2006 Feb;87(Pt 2):255-65.

PMID:
16432010
11.

Novel replication-incompetent vector derived from adenovirus type 11 (Ad11) for vaccination and gene therapy: low seroprevalence and non-cross-reactivity with Ad5.

Holterman L, Vogels R, van der Vlugt R, Sieuwerts M, Grimbergen J, Kaspers J, Geelen E, van der Helm E, Lemckert A, Gillissen G, Verhaagh S, Custers J, Zuijdgeest D, Berkhout B, Bakker M, Quax P, Goudsmit J, Havenga M.

J Virol. 2004 Dec;78(23):13207-15.

12.

Sequencing and chromosomal localization of Fabp6 and an intronless Fabp6 segment in the rat.

Bonné A, Gösele C, den Bieman M, Gillissen G, Kreitler T, Pravenec M, Kren V, van Lith H, van Zutphen B.

Mol Biol Rep. 2003 Sep;30(3):173-6.

PMID:
12974472
13.

Mapping of rabbit microsatellite markers using chromosome-specific libraries.

Korstanje R, Gillissen GF, Versteeg SA, van Oost BA, Bosma AA, Rogel-Gaillard C, van Zutphen LF, van Lith HA.

J Hered. 2003 Mar-Apr;94(2):161-9.

PMID:
12721228
14.

Genetic map of AFLP markers in the rat (Rattus norvegicus) derived from the H x B/Ipcv and B x H/Cub sets of recombinant inbred strains.

Bonné AC, den Bieman MG, Gillissen GF, Kren V, Krenová D, Bílá V, Zídek V, Kostka V, Musilová A, Pravenec M, van Zutphen BF, van Lith HA.

Biochem Genet. 2003 Apr;41(3-4):77-89.

PMID:
12670022
15.

Quantitative trait loci influencing blood and liver cholesterol concentration in rats.

Bonné AC, den Bieman MG, Gillissen GF, Lankhorst A, Kenyon CJ, van Zutphen BF, van Lith HA.

Arterioscler Thromb Vasc Biol. 2002 Dec 1;22(12):2072-9.

PMID:
12482837
16.

Chromosomal localization of genes involved in biosynthesis, metabolism or transport of cholesterol in the rat.

Bonné AC, den Bieman MG, Gillissen GF, van Lith HA, van Zutphen LF.

Cytogenet Genome Res. 2002;97(3-4):183-6.

PMID:
12438711
17.

A rat linkage map based on BC x LEW intercross.

Bonné AC, den Bieman MG, Gillissen GF, van Zutphen LF, van Lith HA.

Folia Biol (Praha). 2002;48(3):120-3.

PMID:
12118726
18.

Mapping of rabbit chromosome 1 markers generated from a microsatellite-enriched chromosome-specific library.

Korstanje R, Gillissen GF, den Bieman MG, Versteeg SA, van Oost B, Fox RR, van Lith HA, van Zutphen LF.

Anim Genet. 2001 Oct;32(5):308-12.

PMID:
11683719
19.

Mapping of a QTL for serum HDL cholesterol in the rabbit using AFLP technology.

Van Haeringen WA, Den Bieman M, Gillissen GF, Lankhorst AE, Kuiper MT, Van Zutphen LF, Van Lith HA.

J Hered. 2001 Jul-Aug;92(4):322-6.

PMID:
11535644
20.

Mapping of microsatellite loci and association of aorta atherosclerosis with LG VI markers in the rabbit.

Korstanje R, Gillissen GF, Kodde LP, Den Bieman M, Lankhorst A, Van Zutphen LF, Van Lith HA.

Physiol Genomics. 2001 Jun 6;6(1):11-8.

PMID:
11395542
21.

[Immunomodulating effects of antibiotics alone and in conjunction with immunosuppressive drugs].

Gillissen G.

Z Arztl Fortbild (Jena). 1992 Mar 25;86(6):263-7. Review. German. No abstract available.

PMID:
1590005
22.

"Inverse" effects of cortisone in experimental infection of mice.

Gillissen G.

Adv Exp Med Biol. 1992;319:137-43.

PMID:
1414589
23.

Modulation of antimicrobial effects of beta-lactams by amino acids in vitro.

Gillissen G, Schumacher M, Breuer-Werle M.

Zentralbl Bakteriol. 1991 Jun;275(2):223-32.

PMID:
1930574
24.
25.

[Interaction of bactericidal serum effect and antibiotics in subminimal inhibitory concentrations on E. coli strains].

Gillissen G, Schumacher M, Breuer-Werle M.

Pathol Biol (Paris). 1990 May;38(5):436-40. French.

PMID:
2195453
26.

[Interpretation of the influence of immunoglobulins and glycine on bacterial sensitivity to antibiotics in vitro].

Gillissen G, Melzer B, Breuer-Werle M.

Pathol Biol (Paris). 1989 May;37(5):341-5. French.

PMID:
2674866
27.

Side effects of antibiotics on immune response parameters and their possible implications in antimicrobial chemotherapy.

Gillissen G.

Zentralbl Bakteriol Mikrobiol Hyg A. 1988 Nov;270(1-2):171-99. Review.

PMID:
3066074
28.

[Effect of fosfomycin on cellular immune reactions as affected by cyclophosphamide or corticosteroids].

Gillissen G, Breuer-Werle M, Ostendorp H.

Pathol Biol (Paris). 1988 Jun;36(5 Pt 2):731-4. French.

PMID:
3054757
29.

[Clavulanic acid. Its effect on Staphylococcus aureus other than its inhibitory effect on beta-lactamases].

Gillissen G, Hasse G.

Pathol Biol (Paris). 1987 May;35(5):503-6. French.

PMID:
3302852
30.

Increased resistance towards two systemic experimental infections by tetrachlorodecaoxygen anion complex. Possible implications of cellular and humoral immunity.

Gillissen G, Kühne FW, Breuer-Werle M, Melzer B, Ostendorp H.

Arzneimittelforschung. 1986 Dec;36(12):1778-82.

PMID:
3566839
31.
32.

[Influence of antibiotics on the production of interleukin-1 by macrophages].

Gillissen G, Melzer B.

Pathol Biol (Paris). 1985 Jun;33(5 Pt 2):521-4. French.

PMID:
3911147
33.

[Evaluation of the modulatory effects of in vivo antibiotics on phagocytosis in mice using various methods].

Gillissen G, Pusztai-Markos Z.

Pathol Biol (Paris). 1984 May;32(5):355-8. French.

PMID:
6330647
34.

Indication of a certain molecular correlation between rat IgE and human IgE.

Gillissen G, Schweizer K, Hoffmann D.

Allergol Immunopathol (Madr). 1984 Mar-Apr;12(2):93-6.

PMID:
6205574
35.

[Effects of Immunoferon on humoral immune response].

Gillissen G, Breuer-Werle M, Schmitz AE.

Rev Clin Esp. 1984 Jan 15;172(1):21-2. Spanish. No abstract available.

PMID:
6709942
36.

[Influence of an immunomodulator on phagocytosis in the clearance test].

Gillissen G, Breuer-Werle M.

Rev Clin Esp. 1984 Jan 15;172(1):17-9. Spanish. No abstract available.

PMID:
6153055
37.

Influence of cefaclor on immune response parameters.

Gillissen G.

Arzneimittelforschung. 1984;34(11):1535-40.

PMID:
6335399
38.

The bilateral effect of theophylline on immune response mechanisms.

Gillissen G.

Allergol Immunopathol (Madr). 1983 Sep-Oct;11(5):321-7.

PMID:
6362378
39.

[Additive effect of an immunomodulator on the therapeutic effect of antibiotics].

Gillissen G, Breuer-Werle M.

Pathol Biol (Paris). 1983 Jun;31(6):548-50. French.

PMID:
6348668
40.

Disodium-cromoglycate and immune response mechanism.

Gillissen G.

Allergol Immunopathol (Madr). 1982 May-Jun;10(3):185-90.

PMID:
6816050
41.
42.

Immune modulating effect of omnadin in experimental infections & its influence on cellular immune reactions.

Gillissen G.

Indian J Exp Biol. 1981 Nov;19(11):1007-10. No abstract available.

PMID:
7338356
43.

Non specific stimulation of immune defence as support of antimicrobial chemotherapy.

Gillissen G.

Methods Find Exp Clin Pharmacol. 1981 Sep-Oct;3(5):297-302.

PMID:
7329158
44.

The influence of sodium 8-chlorotheophyllinate (S8CT) on immune processes.

Gillissen G.

Experientia. 1981 Apr 15;37(4):420-3.

PMID:
7238832
45.

Action of theophylline on humoral and cellular immune response mechanisms.

Gillissen G.

Allergol Immunopathol (Madr). 1981;Suppl 9:218-22. No abstract available.

PMID:
7349730
46.
47.

Cell mediated immune regulation in autoimmunity.

Gillissen G, Pusztai-Markos Z.

Allergol Immunopathol (Madr). 1979 Mar-Apr;7(2):153-68.

PMID:
313696
48.

Variation of lymphocyte classes and their PHA-P reactivity with age.

Gillissen G, Spölgen W, Sticker A.

Z Immunitatsforsch Immunobiol. 1977 Jul;153(2):107-19.

PMID:
303029
49.

Gradient titration of agglutinating antibodies, a new biological method.

Schweizer K, Gillissen G.

Z Immunitatsforsch Exp Klin Immunol. 1974 May;147(1):17-26. No abstract available.

PMID:
4282995
50.

[Immunologically induced inhibition and enhancement of tumor growth (EAT): significance of different antigenic preparations (author's transl)].

Schweizer K, Gillissen G, Lutzeyer W.

Med Microbiol Immunol. 1974 Mar 22;159(3):251-60. German. No abstract available.

PMID:
4830938

Supplemental Content

Loading ...
Support Center